Authors:
CJ Cairney, AE Bilsland, TRJ Evans, J Roffey, DC Bennett, M Narita, CJ Torrance, WN Keith
Journal name: 
Drug Discov Today
Citation info: 
17(5-6):269-276
Abstract: 
Senescence forms a universal block to tumorigenesis which impacts on all hallmarks of cancer, making it an attractive target for drug discovery. Therefore a strategy must be devised to focus this broad potential into a manageable drug discovery programme. Several issues remain to be addressed including the lack of robust senescence-inducing compounds and causally related biomarkers to measure cellular response. Here, we review the latest progress in translating senescence as a target for cancer therapy and some promising approaches to drug and biomarker discovery. Finally, we discuss the potential application of a senescence-induction therapy in a clinical setting.
DOI: 
http://doi.org/10.1016/j.drudis.2012.01.019
Research group: 
Narita Group
E-pub date: 
31 Mar 2012